Navigation Links
Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder

Phase 3 trials conducted on Remicade (infliximab) showed rapid, significant improvement in patients with moderate to severe plaque psoriasis. The stud mainly used placebo-// control and dose-ranging from 3 mg/kg and 5 mg/kg. The continuous eight week maintenance therapy resulted in greater long-term skin clearance compared with as-needed therapy regimens within each dose.

At 10 weeks it was seen that 70 % of the patients treated with Remicade 3 mg/kg and 75 % of patients receiving 5 mg/kg achieved at least 75 % improvement in psoriasis. The measurement scale used was Psoriasis Area Severity Index (PASI 75). At the end of the 50 weeks patients receiving Remicade 5 mg/kg every eight-week maintenance therapy saw the highest level of improvement. The results were presented at the 64th annual American Academy of Dermatology meeting.

Alan Menter, MD, chairman, Division of Dermatology, Baylor University Medical Center, and lead study investigator said that patients receiving scheduled Remicade maintenance therapy achieved long-term cure against psoriasis, a lifelong, chronic inflammatory disease. Statistics show that nearly two million Americans suffer from this disease.

Robert Matheson, MD, Oregon Medical Research Center, and study investigator said that Remicade in the treatment of a disease offers great physical and emotional challenges. It has a potential to result in complete skin clearance.

The United States Food and Drug Administration (FDA) accepted the use of Remicade in the treatment of moderate to severe plaque psoriasis. Hence the European Commission also approved Remicade for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to other systemic therapy.


'"/>




Page: 1

Related medicine news :

1. Remicade Therapy Effective in Treating Severe Psoriasis
2. Sanitation Emerges as the Winner
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Treatment for Menieres disease
6. Treatment for pre-menstrual syndrome is ineffective
7. Better Treatment for obesity
8. Gene Treatment for Heart Disease
9. More People Seeking Treatment for Depression
10. Focused Treatment For Childhood Cancer
11. Inadequate Drug Treatment For Youth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/10/2016)... ... 10, 2016 , ... "TransPanel Volume 2 is a package of fading panel ... - CEO of Pixel Film Studios. , TransPanel Volume 2 is a set ... set of versatile transitions features presets with up to 4 panels with complementary line ...
(Date:12/9/2016)... ... 2016 , ... Groth Family Insurance, a Washington-based firm offering ... a charity drive to support the family of Cindy Hendrickson, a local mother ... On October 29th of this year, Cindy Hendrickson swerved to avoid an oncoming ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The report forecasts the global optical ... period 2016-2020. The report covers the present scenario ... 2016-2020. To calculate the market size, the report considers the revenue ...
(Date:12/9/2016)... 9, 2016 Mitsubishi Tanabe Pharma Corporation (Head ... Director, CEO: Dr. Masayuki Mitsuka ) has presented ... given edaravone intravenously in 10-14 day cycles for 48 ... the ALS Functional Rating Scale-Revised (ALSFRS-R). The data were ... ALS/MND in Dublin, Ireland . ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
Breaking Medicine Technology: